A Study of RO4989991 in Patients With Allergic Rhinitis
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, observer-blinded, placebo-controlled study will evaluate the
safety and tolerability of subcutaneous doses of RO4989991 in patients with allergic rhinitis
who are otherwise healthy. The anticipated time on study treatment is 2 weeks.